Covid-19 has exposed the limits of the pharmaceutical market model

That so much hope is being pinned on remdesivir, the drug Gilead is testing for Covid-19, reflects the failure of our system for new drug development rather than the unqualified success some commentators are making it out to be.

If anything, remdesivir is the poster child for why we need a new model of drug development for pandemics and neglected diseases that isn’t restricted by the current market-based model.